Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ziprasidone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Ziprasidone. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-003156-35 Sponsor Protocol Number: EXPSY 0105 Start Date*: 2005-12-01
    Sponsor Name:Department of Psychiatry and Psychotherapy (Cologne)
    Full Title: Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study
    Medical condition: Patients with schizophrenia and cannabis abuse/dependency will be randomized to ziprasidone or clozapine treatment. Dose of medication and frequency of administration will be flexible and adjustab...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002147-27 Sponsor Protocol Number: Start Date*: 2005-05-26
    Sponsor Name:Department of General Psychiatry
    Full Title: Influence of treatment of olanzapine and ziprasidone on transcapillary glucose transport in human skeletal muscle
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000223-42 Sponsor Protocol Number: ZiSe Start Date*: 2005-10-31
    Sponsor Name:University Hospital Hamburg-Eppendorf, Psychiatry
    Full Title: Effects of ziprasidone vs. placebo during the first four weeks of eight weeks sertraline treatment in patients with posttraumatic stress disorder (PTSD)
    Medical condition: Post-traumatic Stress Disorder (PTSD) according to DSM-IV criteria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004391-21 Sponsor Protocol Number: A1281147 Start Date*: 2006-06-23
    Sponsor Name:Pfizer S.A.
    Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP STUDY, COMPARING THE EFFICACY AND TOLERABILITY OF ZIPRASIDONE (ZELDOX®, GEODON®) VS OLANZAPINE (ZYPREXA®) IN THE TREATMENT AND MAINTENANCE OF...
    Medical condition: Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004939 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Prematurely Ended) DE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004501-28 Sponsor Protocol Number: ZA001 Start Date*: 2007-12-20
    Sponsor Name:Department of Psychiatry, Ludwig-Maximilians-University Munich
    Full Title: Study to compare the efficacy of ziprasidone (Zeldox) and aripiprazole (Abilify) on cognitive functioning and quality of sleep in the treatment of schizophrenic patients
    Medical condition: Schizophrenia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000606-20 Sponsor Protocol Number: A1281132 Start Date*: 2015-04-03
    Sponsor Name:Pfizer, Inc.
    Full Title: Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Dis...
    Medical condition: Bipolar Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005501-28 Sponsor Protocol Number: A1281134 Start Date*: 2006-05-04
    Sponsor Name:Pfizer AB
    Full Title: Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10039626 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003972-42 Sponsor Protocol Number: A1281198 Start Date*: 2020-08-21
    Sponsor Name:Pfizer, Inc.
    Full Title: A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPO...
    Medical condition: Bipolar Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10004938 Bipolar disorders HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-004088-26 Sponsor Protocol Number: A1281201 Start Date*: 2020-09-03
    Sponsor Name:Pfizer, Inc.
    Full Title: 26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC)
    Medical condition: Bipolar Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10004938 Bipolar disorders HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004167-27 Sponsor Protocol Number: A1281137 Amendment 1 Start Date*: 2006-01-25
    Sponsor Name:Pfizer, S.A.
    Full Title: A Phase 3, randomized, 6-month, double blind trial in subjects with Bipolar I Disorder to evaluate the continued safety and maintenance of effect of Ziprasidone plus a mood stabilizer (vs placebo p...
    Medical condition: Bipolar I Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.0 10004939 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) SE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002207-13 Sponsor Protocol Number: NRA1280023 Start Date*: 2006-06-29
    Sponsor Name:Dept. Child & Adolescent Psychiatry Univ. Freiburg
    Full Title: Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial
    Medical condition: conduct disorder (CD), oppositional defiant disorder (ODD) and disruptive behavior disorder not otherwise specified (DBD-NOS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011097-15 Sponsor Protocol Number: OLA_ZIPRA Start Date*: 2009-08-25
    Sponsor Name:Medizinische Universität Wien, Universitätsklinik für Klinische Pharmakologie
    Full Title: Effect of atypical antipsychotics on gene expression in soft tissues of healthy subjects. A placebo controlled randomised pilot study.
    Medical condition: The study will be conducted in 42 healthy volunteers
    Disease:
    Population Age: Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000607-15 Sponsor Protocol Number: A1281133 Start Date*: 2015-04-09
    Sponsor Name:Pfizer Inc
    Full Title: 26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)
    Medical condition: Bipolar Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005502-23 Sponsor Protocol Number: A1281135 Start Date*: 2006-05-04
    Sponsor Name:Pfizer AB
    Full Title: 26-week open-label extension study evaluating the safety and tolerability of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia.
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.0 10039626 LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003475-13 Sponsor Protocol Number: A1281148 Start Date*: 2006-12-08
    Sponsor Name:Pfizer Pharma GmbH
    Full Title: A SIXTEEN-WEEK, MULTI-CENTER, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF SWITCHING FROM QUETIAPINE TO ZIPRASIDONE IN SUBJECTS DIAGNOSED WITH SCHIZOPHRENIA OR SCHIZOAFFECT...
    Medical condition: Schizophrenia and Schizoaffective Disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039635 Schizophrenia schizoaffective LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004036-71 Sponsor Protocol Number: 17-217 Start Date*: 2006-09-21
    Sponsor Name:Medizinische Universität Graz
    Full Title: Zur Frage des neuroleptikainduzierten metabolischen Syndroms. Studie 2: Fettverteilung und spezifische hormonelle Parameter. Vergleich zwischen auf das metabolische Syndrom vulnerablen und nicht vu...
    Medical condition: Bereits bekannte psychotische Erkrankung (Schizophrenie, schizoaffektive Störung, akut polymorph psychotische Störung) mit einer nicht tolerablen Gewichtssteigerung oder/und metabolischen Veränderu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004034-32 Sponsor Protocol Number: 17-216 Start Date*: 2006-09-20
    Sponsor Name:Medizinische Universität Graz
    Full Title: Zur Frage des neuroleptikainduzierten metabolischen Syndroms. Studie 1: Fettverteilung und spezifische hormonelle Parameter. Eine prospektive Vergleichsstudie zwischen 5 atypischen Neuroleptika
    Medical condition: Einschlusskriterien: - Schizophrenie, schizoaffektive Störung oder akut polymorph psychotische Störung - Alter: zwischen 18 und 70 Jahren - Vorliegen einer schriftlichen Einverständniserklärung zu...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000418-13 Sponsor Protocol Number: M10-855 Start Date*: 2012-12-21
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS)
    Medical condition: Cognitive Deficits in Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003080-31 Sponsor Protocol Number: 172003 Start Date*: 2006-12-12
    Sponsor Name:NV Organon
    Full Title: A multi-center, double-blind, flexible-dose efficacy trial with Org 25935 versus placebo as add-on therapy in subjects with predominant, persistent negative symptoms of schizophrenia treated with a...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) FR (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002213-19 Sponsor Protocol Number: ELICE-BD-O1 Start Date*: 2019-09-19
    Sponsor Name:University of British Columbia
    Full Title: A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Pa...
    Medical condition: Euthymic Bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:57:06 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA